PharmaCyte Biotech (PMCB) EBITDA (2010 - 2026)
PharmaCyte Biotech (PMCB) EBITDA from Jul 31, 2010 to Jan 31, 2026. The TTM PharmaCyte Biotech (PMCB) EBITDA is -$3.28M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
PharmaCyte Biotech (PMCB) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 3 Years TTM | -16.38% |
| 5 Years TTM | -0.36% |
| 10 Years TTM | -0.48% |
| All Time TTM | +4.55% |
Annual EBITDA change of PharmaCyte Biotech (PMCB)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | $750K | -97.55% |
| 2025 | $31M | +9190.91% |
| 2024 | $330K | -107.64% |
| 2023 | -$4.32M | +1.89% |
| 2022 | -$4.24M | +19.44% |
| 2021 | -$3.55M | -7.31% |
| 2020 | -$3.83M | -5.90% |
| 2019 | -$4.07M | -40.41% |
| 2018 | -$6.83M | +53.83% |
| 2017 | -$4.44M | -26.73% |
| 2016 | -$6.06M | +269.51% |
| 2015 | -$1.64M | -42.66% |
| 2014 | -$2.86M | -49.47% |
| 2013 | -$5.66M | +194.79% |
| 2012 | -$1.92M | +61.34% |
| 2011 | -$1.19M | +376.00% |
| 2010 | -$250K | N/A |
Comparison PharmaCyte Biotech (PMCB) five years EBITDA CAGR with competitors
PharmaCyte Biotech (PMCB) five years EBITDA CAGR is -0.35%.